ATE167473T1 - Sulfonamid-derivate - Google Patents

Sulfonamid-derivate

Info

Publication number
ATE167473T1
ATE167473T1 AT91113256T AT91113256T ATE167473T1 AT E167473 T1 ATE167473 T1 AT E167473T1 AT 91113256 T AT91113256 T AT 91113256T AT 91113256 T AT91113256 T AT 91113256T AT E167473 T1 ATE167473 T1 AT E167473T1
Authority
AT
Austria
Prior art keywords
group
different
same
hydrogen atom
another
Prior art date
Application number
AT91113256T
Other languages
English (en)
Inventor
Hiroshi Yoshino
Norihiro Ueda
Hiroyuki Sgumi
Jun Niijima
Yoshihiko Kotake
Toshimi Okada
Nozomu Koyanagi
Tatsuo Watanabe
Makoto Asada
Kentaro Yoshimatsu
Atsumi Iijima
Takeshi Nagasu
Kappei Tsukahara
Kyosuke Kitoh
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE167473T1 publication Critical patent/ATE167473T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
AT91113256T 1990-08-20 1991-08-07 Sulfonamid-derivate ATE167473T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21871090 1990-08-20
JP3850991 1991-03-05
JP12104191 1991-05-27

Publications (1)

Publication Number Publication Date
ATE167473T1 true ATE167473T1 (de) 1998-07-15

Family

ID=27289857

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91113256T ATE167473T1 (de) 1990-08-20 1991-08-07 Sulfonamid-derivate

Country Status (15)

Country Link
US (6) US5250549A (de)
EP (1) EP0472053B1 (de)
KR (1) KR950001686B1 (de)
CN (2) CN1036650C (de)
AT (1) ATE167473T1 (de)
AU (1) AU636239B2 (de)
CA (1) CA2049496C (de)
DE (1) DE69129611T2 (de)
FI (1) FI913815A (de)
HU (1) HUT59663A (de)
IE (1) IE912936A1 (de)
NO (1) NO178695C (de)
NZ (1) NZ239425A (de)
RU (1) RU2059615C1 (de)
TW (1) TW206208B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
IT1256354B (it) * 1992-08-31 1995-12-01 Francesca Pelizzoni Derivati della combretastatina ad attivita' anti-tumorale e procedimento per la loro preparazione
US5834462A (en) * 1993-07-26 1998-11-10 Eisai Co., Ltd. Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives
JP3080405B2 (ja) * 1994-04-06 2000-08-28 日本新薬株式会社 アミノスチルバゾール誘導体及び医薬
CA2150609C (en) * 1994-06-01 1998-12-08 Mikiro Yanaka Pyrimidine derivatives and pharmaceutical composition
PT799206E (pt) * 1994-12-20 2003-01-31 Hoffmann La Roche Derivados de aril- e heteroaril-sulfonamida processo para a sua preparacao e sua utilizacao como antagonistas da endotelina
CN1063443C (zh) * 1995-03-28 2001-03-21 日本脏器制药株式会社 新的苯并噻唑衍生物
ATE249213T1 (de) * 1996-02-22 2003-09-15 Tularik Inc Pentafluorobenzensulfonamiden und analoge
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
DK0939627T3 (da) * 1996-07-19 2003-10-13 Tularik Inc Pentaflourbenzensulfonamider og analoger
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
KR20010012868A (ko) 1997-05-30 2001-02-26 다께다 가즈히꼬 신규 설폰아미드 유도체
ATE279387T1 (de) * 1997-07-25 2004-10-15 Nippon Kayaku Kk Verbindungen zur förderung der neuronendifferenzierung
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
NZ503809A (en) * 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
DE19802437A1 (de) * 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
CA2335559A1 (en) 1998-06-25 1999-12-29 Tularik Inc. Arylsulfonanilide phosphates
US6153585A (en) * 1998-07-20 2000-11-28 Tularik Inc. Arylsulfonanilide derivatives
EP1285911A3 (de) * 1998-09-23 2003-03-26 Tularik Inc. Arylsulfonylanilid-Harnstoffe
US6214880B1 (en) 1998-09-23 2001-04-10 Tularik Inc. Arylsulfonanilide ureas
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
ES2241639T3 (es) 1999-07-29 2005-11-01 Amgen, Inc. Terapia de combinacion que usa un compuesto de pentafluorobencensulfonamidas y platino.
TWI271192B (en) * 1999-11-11 2007-01-21 Kyorin Pharmaceutical Co Ltd Solid formulation for oral administration
AU781365B2 (en) 1999-12-21 2005-05-19 Icagen, Inc. Potassium channel inhibitors
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6566380B2 (en) 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
FR2827280B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
CA2506983C (en) * 2002-11-26 2010-03-30 Institute Of Virology Ca ix-specific inhibitors
US7833734B2 (en) * 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
US20040242649A1 (en) * 2003-05-29 2004-12-02 Hagey Anne E. Extended dosing regimen
JP2007500240A (ja) * 2003-05-29 2007-01-11 アボット・ラボラトリーズ Ａｂｔ−７５１による持続投与レジメン
US7393873B2 (en) * 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節
CA2567838A1 (en) * 2004-05-28 2005-12-15 Abbott Laboratories Treatment of cancer in pediatric patients
KR100839511B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 은-함유 설파제를 디아조화체로 하는 산성 항균 염료와그의 제조 방법 및 그를 이용한 항균 섬유
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
WO2006047302A1 (en) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
MX2007008509A (es) * 2005-01-13 2007-09-04 Abbott Lab Forma cristalina 2 de n-((2z)-2-((4-hidroxifenil)imino)-1,2- dihidro-3-piridinil)-4-metoxibencenosulfonamida.
US20060293367A1 (en) * 2005-01-13 2006-12-28 Zhang Geoff G Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide
US20070021471A1 (en) * 2005-01-13 2007-01-25 Jorge Gandarilla Crystalline N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide ethanolates
US20060293368A1 (en) * 2005-01-13 2006-12-28 Zhang Geoff G Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride
US20070004781A1 (en) * 2005-01-13 2007-01-04 Schmitt Eric A Crystalline N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride
WO2006076511A1 (en) * 2005-01-13 2006-07-20 Abbott Laboratories N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide crystalline form 1
US20070021470A1 (en) * 2005-01-13 2007-01-25 Jorge Gandarilla Crystalline N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide methanolates
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
EP2354126B1 (de) * 2005-01-14 2013-09-25 ChemoCentryx, Inc. Heteroarylsulfonamide und CCR2
KR100821898B1 (ko) * 2005-02-23 2008-04-16 주식회사 코오롱 은 함유 항균 산성 염료와 그의 제조 방법 및 그를 이용한항균 섬유
KR100821900B1 (ko) * 2005-09-15 2008-04-16 주식회사 코오롱 항균 산성 염료와 그의 제조 방법 및 그를 이용한 항균섬유
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
GB0524786D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
BRPI0813695B8 (pt) 2007-07-12 2021-05-25 Chemocentryx Inc compostos de heteroaril piridil e fenil benzenossulfonamidas fundidas, composição, método de modular a função de ccr2, usos dos compostos e forma cristalina
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2723961C (en) 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
EP2374802B1 (de) 2008-11-10 2014-04-23 Kyowa Hakko Kirin Co., Ltd. Inhibitor der kynureninproduktion
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012142698A1 (en) * 2011-04-20 2012-10-26 Universite Laval Alkylurea derivatives active against cancer cells
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2013055793A1 (en) 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
JP6564380B2 (ja) 2013-09-20 2019-08-21 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 前立腺癌を治療するための化合物
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2016007993A1 (en) * 2014-07-16 2016-01-21 University Of South Australia Benzene sulfonamide-based inhibitors of sphingosine kinase
JP6578349B2 (ja) 2014-08-11 2019-09-18 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
EP3240778A4 (de) 2014-12-31 2018-07-11 Angion Biomedica Corp. Verfahren und mittel zur behandlung von krankheiten
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
AU2018347361A1 (en) 2017-10-11 2020-04-30 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
WO2019139979A2 (en) * 2018-01-09 2019-07-18 The Scripps Research Institute Arylfluorosulfate compounds and methods
US11286236B2 (en) 2018-06-05 2022-03-29 Vector Vitale Ip Llc Compound, agent and composition for the suppression of cancer growth
CN109331868B (zh) * 2018-09-29 2021-03-26 广东工业大学 一种苯甘氨酸类双官能团催化剂及其制备方法和应用
JP2022551943A (ja) * 2019-10-11 2022-12-14 ヴェクター ヴィターレ アイピー エルエルシー パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
EP4093398A1 (de) 2020-01-22 2022-11-30 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Abt-751 und ionisierende strahlung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2307650A (en) * 1938-11-29 1943-01-05 Nepera Chemical Company Inc Sulphanilamido-amino-pyridines and processes for producing the same
US2202933A (en) * 1939-08-30 1940-06-04 Nepera Chemical Co Inc Sulphanilamido-aminopyridines and process for producing the same
DE1670761A1 (de) * 1966-10-27 1970-12-23 Forsch Borstel Inst Fuer Exper Verfahren zur Herstellung von in 3- oder 5-Stellung durch elektronegative Substituenten substituierten 2-Sulfanil-amido-pyridinen
DE3686688T2 (de) * 1985-06-24 1993-03-18 Merck & Co Inc Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
JPH0610174B2 (ja) * 1986-09-29 1994-02-09 株式会社大塚製薬工場 アミノフエノ−ル誘導体

Also Published As

Publication number Publication date
EP0472053A2 (de) 1992-02-26
US5610304A (en) 1997-03-11
FI913815A0 (fi) 1991-08-12
RU2059615C1 (ru) 1996-05-10
CA2049496A1 (en) 1992-02-21
TW206208B (de) 1993-05-21
NZ239425A (en) 1993-10-26
AU8249391A (en) 1992-02-27
CA2049496C (en) 1997-02-04
HU912676D0 (en) 1992-01-28
NO913207L (no) 1992-02-21
KR920004341A (ko) 1992-03-27
CN1136036A (zh) 1996-11-20
CN1036650C (zh) 1997-12-10
NO178695B (no) 1996-02-05
KR950001686B1 (ko) 1995-02-28
NO178695C (no) 1996-05-15
US5610320A (en) 1997-03-11
NO913207D0 (no) 1991-08-16
EP0472053A3 (en) 1994-08-10
US5434172A (en) 1995-07-18
EP0472053B1 (de) 1998-06-17
US5332751A (en) 1994-07-26
FI913815A (fi) 1992-02-21
AU636239B2 (en) 1993-04-22
US5250549A (en) 1993-10-05
DE69129611D1 (de) 1998-07-23
CN1059519A (zh) 1992-03-18
IE912936A1 (en) 1992-02-26
HUT59663A (en) 1992-06-29
DE69129611T2 (de) 1998-12-17
US5292758A (en) 1994-03-08

Similar Documents

Publication Publication Date Title
ATE167473T1 (de) Sulfonamid-derivate
ATE255564T1 (de) Imidazolderivat
DK345989D0 (da) Quinolinderivater
ATE88714T1 (de) 2'-desoxy-5-fluoruridinderivate.
DE69015541T2 (de) Chinolinderivate, deren Herstellung und Verwendung.
DK291488D0 (da) Alkansulfonanilidderivater
DE3688950T2 (de) Substituierte Chinolinderivate.
ES2127762T3 (es) Quinoleinas 2-sustituidas para el tratamiento de las leismaniosis.
DK0601191T3 (da) Hidtil ukendt tetracyklisk forbindelse
DE60221251D1 (de) Bis(2-aryl-5-pyridyl)derivate
DE69526332D1 (de) Indol-derivate
BG60248B2 (en) Process for the preparation of phenoxyethylamine derivatives
ATE367377T1 (de) Bis(5-aryl-2-pyridyl)derivate
MY104048A (en) New allylaminoethylazoles.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties